Obsidian Therapeutics director reports option holdings

Obsidian Therapeutics, Inc. director Robert W. Ross reported his initial beneficial ownership, consisting solely of stock options over common stock.

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. director Robert W. Ross reported his initial beneficial ownership, consisting solely of stock options over common stock. The reported positions include options exercisable at $0.71 per share for 180,000 underlying shares, fully vested and exercisable, and additional options exercisable at $0.78 per share for 175,000 and 162,500 underlying shares. The latter grant vests in sixteen equal quarterly installments following June 25, 2024, subject to his continued service.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider ROSS ROBERT W.

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F1	--	--	--
holding	Stock Option (Right to Buy) F2	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 517,500 contracts (Direct)

Footnotes (2)

1. F1. The shares underlying this option are fully vested and exercisable.
2. F2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option exercise price: $0.71 per share Underlying shares: 180,000 shares Option exercise price: $0.78 per share +5 more

8 metrics

Option exercise price $0.71 per share Stock option over 180,000 underlying common shares, fully vested and exercisable

Underlying shares 180,000 shares Common stock underlying fully vested option at $0.71 per share

Option exercise price $0.78 per share Two stock option positions over 175,000 and 162,500 underlying common shares

Underlying shares 175,000 shares Common stock underlying $0.78 option expiring September 20, 2031

Underlying shares 162,500 shares Common stock underlying $0.78 option with quarterly vesting, expiring June 24, 2034

Option expiration date July 14, 2030 Expiration of $0.71 stock option over 180,000 underlying shares

Option expiration date September 20, 2031 Expiration of $0.78 stock option over 175,000 underlying shares

Option expiration date June 24, 2034 Expiration of $0.78 stock option over 162,500 underlying shares

Key Terms

Stock Option (Right to Buy), underlying security shares, fully vested and exercisable, vest in sixteen (16) equal quarterly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

underlying security shares financial

"underlying_security_shares: 180000.0000"

fully vested and exercisable financial

"The shares underlying this option are fully vested and exercisable."

vest in sixteen (16) equal quarterly installments financial

"The shares underlying this option vest in sixteen (16) equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for OBX disclose about Robert W. Ross?

The Form 3 shows that director Robert W. Ross holds three stock option positions over Obsidian Therapeutics common stock, with exercise prices of $0.71 and $0.78 per share and varying expiration dates through 2034.

How many OBX shares are covered by Robert W. Ross’s fully vested option?

One option held by Robert W. Ross covers 180,000 underlying OBX common shares at an exercise price of $0.71 per share. A footnote states these shares are fully vested and exercisable as of the reported date.

What are the vesting terms of Robert W. Ross’s 0.78 OBX stock options?

One $0.78 option for 162,500 underlying OBX shares vests in sixteen equal quarterly installments following June 25, 2024, subject to his continued service on each vesting date, while another $0.78 option for 175,000 shares is already fully vested.

Do the OBX options held by Robert W. Ross have stated expiration dates?

Yes. The reported stock options expire on July 14, 2030, September 20, 2031, and June 24, 2034, respectively, if not exercised earlier, according to the derivative holdings information in the Form 3.

Does the OBX Form 3 show any recent stock purchases or sales by Robert W. Ross?

No. The Form 3 lists holding entries only for stock options and shows no buy or sell transactions. It serves as an initial statement of beneficial ownership rather than a record of recent trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 07:10 PM Accepted by SEC EDGAR 08/03/2026 - 06:29 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ROSS ROBERT W.

(Last) (First) (Middle)

OBSIDIAN THERAPEUTICS, INC.

1030 MASSACHUSETTS AVE

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/03/2026

3. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	07/14/2030	Common Stock	180,000	$0.71	D
Stock Option (Right to Buy)	(1)	09/20/2031	Common Stock	175,000	$0.78	D
Stock Option (Right to Buy)	(2)	06/24/2034	Common Stock	162,500	$0.78	D

Explanation of Responses:

1. The shares underlying this option are fully vested and exercisable.

2. The shares underlying this option vest in sixteen (16) equal quarterly installments following June 25, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Gabriela Morales-Riverea, Attorney-in-Fact	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)